<div id="readability-page-1"><p>Revolve Wealth Partners LLC cut its stake in  Amgen Inc. (NASDAQ:AMGN - Free Report) by 45.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor  owned 14,461 shares of the medical research company's stock after selling 12,066 shares during the quarter. Revolve Wealth Partners LLC's holdings in Amgen were worth $4,081,000 at the end of the most recent quarter.</p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>Other hedge funds and other institutional investors also recently modified their holdings of the company. Fairvoy Private Wealth LLC lifted its holdings in  Amgen by 1.1% in the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock worth $885,000 after buying an additional 35 shares during the period.  Nicholson Wealth Management Group LLC raised its position in shares of  Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock worth $1,652,000 after acquiring an additional 35 shares in the last quarter.  Crumly &amp; Associates Inc. lifted its stake in shares of  Amgen by 3.2% in the 2nd quarter. Crumly &amp; Associates Inc. now owns 1,146 shares of the medical research company's stock valued at $320,000 after purchasing an additional 36 shares during the period.  Maryland Capital Advisors Inc. boosted its position in shares of  Amgen by 5.2% during the second quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company's stock valued at $204,000 after purchasing an additional 36 shares in the last quarter.  Finally, Lion Street Advisors LLC boosted its position in shares of  Amgen by 1.3% during the second quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company's stock valued at $774,000 after purchasing an additional 36 shares in the last quarter. Hedge funds and other institutional investors own  76.50% of the company's stock. </p><h2>Insider Buying and Selling</h2><p>In related news, EVP Murdo Gordon sold 6,879 shares of the business's stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 in the last three months. Insiders own  0.69% of the company's stock. </p><h2>Analyst Ratings Changes</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>AMGN has been the subject of a number of research reports. Wall Street Zen upgraded Amgen from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, December 15th. Guggenheim upped their target price on shares of Amgen from $288.00 to $305.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. Daiwa Capital Markets increased their price target on shares of Amgen from $310.00 to $370.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, November 18th. The Goldman Sachs Group  reissued a &#34;buy&#34; rating on shares of Amgen in a research note on Tuesday, November 25th. Finally, Scotiabank initiated coverage on shares of Amgen in a report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $385.00 price objective on the stock. One analyst  has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have issued  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $332.85.</p><p><b>Check Out Our Latest Analysis on AMGN</b></p><h2>Amgen Price Performance</h2><ul><li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li></ul><p>AMGN opened at $331.39 on Tuesday. The firm has a market cap of $178.45 billion, a PE ratio of 25.61, a P/E/G ratio of 3.11 and a beta of 0.45. The stock has a 50-day moving average price of $320.10 and a 200-day moving average price of $300.60. Amgen Inc. has a 1 year low of $257.05 and a 1 year high of $346.38. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. </p><p>Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen's revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.  Sell-side analysts predict that  Amgen Inc. will post 20.62 earnings per share for the current fiscal year. </p><h2>Amgen Increases Dividend</h2><p>The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. This is an increase from Amgen's previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen's payout ratio is 73.57%. </p><h2>Amgen Profile</h2> (Free Report)<p>Amgen Inc <span>NASDAQ: AMGN<span></span></span> is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.  </p><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Amgen</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>The Last Gold Bull Market </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amgen Right Now?</h2><p>Before you consider Amgen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMGN

<p>Revolve Wealth Partners LLC reduced its stake in Amgen Inc. by 45.5% in Q3, selling 12,066 shares. Insiders sold 10,908 shares worth $3.67 million recently. Analysts have mixed ratings, with a Moderate Buy consensus and an average price target of $332.85. Amgen's stock opened at $331.39, with a market cap of $178.45 billion.</p>

Revolve Wealth Partners LLC Sells 12,066 Shares of Amgen Inc. $AMGN